SciClone reevaluates clinical strategy

SciClone Pharmaceuticals Inc. is rethinking its clinical priorities in the wake of the failure of a Phase III study of its Zadaxin thymosin alpha-1 to show statistical significance in treating chronic hepatitis B.

SCLN (San Mateo, Calif.) published an abstract of Phase III data to be presented at a

Read the full 487 word article

How to gain access

Continue reading with a
two-week free trial.